title: Effective protection and controlled release of insulin by cationic beta-cyclodextrin polymers from alginate/chitosan nanoparticles.
abstract: In an alginate/chitosan nanoparticle system, insulin was protected by forming complexes with cationic beta-cyclodextrin polymers (CPbetaCDs), which were synthesized from beta-cyclodextrin (beta-CD), epichlorohydrin (EP) and choline chloride (CC) through a one-step polycondensation. Due to the electrostatic attraction between insulin and CPbetaCDs, as well as the assistance of its polymeric chains, CPbetaCDs could effectively protect insulin under simulated gastrointestinal conditions. The nanoparticles have their mean size lower than 350 nm and can load insulin with the association efficiency (AE) up to 87%. It is notable that the cumulative insulin release in simulated intestinal fluid was significantly higher (40%) than that without CPbetaCDs (18%) because insulin was mainly retained in the core of the nanoparticles and well protected against degradation in simulated gastric fluid. Far-UV circular dichroism analysis also corroborated the preservation of insulin structure during the nanoparticle preparation and release process.
authors.affiliation: College of Polymer Science and Engineering, Sichuan University, Chengdu 610065, China.
authors.forename: Nan
authors.initials: N
authors.lastname: Zhang
authors.forename: Jiahui
authors.initials: J
authors.lastname: Li
authors.forename: Wenfeng
authors.initials: W
authors.lastname: Jiang
authors.forename: Chunhong
authors.initials: C
authors.lastname: Ren
authors.forename: Jianshu
authors.initials: J
authors.lastname: Li
authors.forename: Jianyu
authors.initials: J
authors.lastname: Xin
authors.forename: Ke
authors.initials: K
authors.lastname: Li
mesh_terms: D000284:Administration, Oral; D000464:Alginates / Q000737:chemistry; D002626:Chemistry, Pharmaceutical; D048271:Chitosan / Q000031:analogs & derivatives / Q000737:chemistry*; D002794:Choline / Q000737:chemistry; D002942:Circular Dichroism; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D004339:Drug Compounding; D004355:Drug Stability; D004811:Epichlorohydrin / Q000737:chemistry; D005750:Gastric Juice / Q000737:chemistry; D020723:Glucuronic Acid / Q000737:chemistry; D006603:Hexuronic Acids / Q000737:chemistry; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000737:chemistry*; D007328:Insulin / Q000008:administration & dosage / Q000737:chemistry*; D007419:Intestinal Secretions / Q000737:chemistry; D007700:Kinetics; D053758:Nanoparticles; D010434:Pepsin A / Q000737:chemistry; D012995:Solubility; D013678:Technology, Pharmaceutical / Q000379:methods; D047392:beta-Cyclodextrins / Q000737:chemistry*
chemical_list: D000464:Alginates; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D006603:Hexuronic Acids; D007004:Hypoglycemic Agents; D007328:Insulin; D047392:beta-Cyclodextrins; D004811:Epichlorohydrin; D020723:Glucuronic Acid; D048271:Chitosan; D010434:Pepsin A; D002794:Choline